Estrogen-dependent breast cancer (EDBC) is a kind of common malignant tumor in postmenopausal women with growing tendency in recent years. Aromatase (AR) is the key enzyme responsible for estrogen biosynthesis and has been considered as an important target for designing inhibitors as potent therapeutic agents for EDBC. AR inhibitors (AIs) are divided into steroidal and nonsteroidal compounds, and the latter shows high inhibitory potency against AR. This review summarizes recent advancement in nonsteroidal AIs.
Keywords: Estrogen-dependent breast cancer, postmenopausal women, aromatase, aromatase inhibitors, nonsteroida, Nonsteroidal Aromatase Inhibitors, Aromatase (AR), therapeutic agents, nonsteroidal, peripheral tissues, endocrine therapy, multienzymatic complex, granulosa, luteal cells, glycosylated cytochrome P450, C19 androgenic, ovarian granulosa cells, prostaglandin E2 (PGE2), cellular transformation, oncogenesis, inflammatory cytokines, (EGFR) HER-2, COX-2, PGE2, CYP19, letrozole, anastrozole, tolerability, mammary tumors, long-term tamoxifen treatment, traditional Chinese medicine, flavanone, liquiritigenin, inhibitory potency, pyridinecontaining (E)-isomer, aminoglutethimide, Isoflavones, prostate cancer, imidazolic, Dual Aromatase-Sulfatase Inhibitors, Estrone 3-sulfamate (EMATE), YM511, Nimesulide Analogues, breast adipose stromal, celecoxib, Estrogen receptor
Rights & PermissionsPrintExport